Tarsus Pharmaceuticals (TARS)

Executive Summary

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing novel therapies for ophthalmic and systemic diseases with high unmet need. Its lead product, XDEMVY (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis, addressing a condition affecting millions. The company is leveraging its expertise in anti-parasitic therapeutics to build a pipeline targeting meibomian gland disease, rosacea, and other conditions. With XDEMVY gaining market traction and multiple pipeline assets advancing, Tarsus is positioned for growth in the ophthalmic space. The company's commercial execution and clinical data readouts will be key drivers of value.

Upcoming Catalysts (preview)

• Q3 2026XDEMVY commercial revenue update and launch trajectory100% success
• TBDPhase 2 data for lotilaner in ocular rosacea (NCT07443202)60% success
• TBDPhase 3 initiation for TP-03 in meibomian gland disease70% success